New drug combo targets Hard-to-Treat cancers

NCT ID NCT06730750

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-stage trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BMS-986490 (a drug) and bevacizumab (a drug)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that express CEACAM5.
What could go wrong: This is an early, first-in-human trial, so safety and effectiveness are not yet known. Many experimental drugs fail in early testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastric cancer gastric neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Local Institution - 0004
ACTIVE_NOT_RECRUITING

Hackensack, New Jersey, 07601, United States
Local Institution - 0006
ACTIVE_NOT_RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Local Institution - 0007
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90033, United States
Local Institution - 0017
ACTIVE_NOT_RECRUITING

Grand Rapids, Michigan, 49546, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Tasman Oncology Research
RECRUITING

Southport, Queensland, 4215, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.